Skip to main content
. 2019 Nov 20;7:185. doi: 10.1186/s40478-019-0826-z

Fig. 6.

Fig. 6

Actionable markers in brain tumours. a overview of expression of potentially actionable targets in a subset of patients, expressed as fold change compared to the mean of the entire group. For clarity only tyrosine kinases are shown for a small selection of patients. b comparative analysis of a primary pleomorphous xantoastrocytoma and its recurrence 4 years later. c shows a selection of actionable targets in sample 13–05, a metastasis of a lung cancer. Note high expression levels of the macrophage receptor RON, MET and CTLA-4. Also VEGF isoforms 121 and 189 are detected